What's Happening?
Aurinia Pharmaceuticals Inc. has announced the initiation of a Phase 4 multicenter study named PRESERVE, which will investigate the combination of LUPKYNIS and other biologic agents such as belimumab, obinutuzumab, or anifrolumab in patients with lupus
nephritis. The study aims to enroll approximately 150 patients across 50 sites in the United States. The primary endpoint is to achieve a complete renal response (CRR) at six months. LUPKYNIS is currently the only FDA-approved oral therapy for lupus nephritis, and the study seeks to improve patient outcomes by combining it with other agents that target different biological pathways involved in the disease.
Why It's Important?
This study is significant as it addresses the ongoing unmet need in the treatment of lupus nephritis, a severe kidney condition associated with systemic lupus erythematosus (SLE). Despite recent advancements, many patients do not achieve the desired CRR within six to twelve months of treatment. By exploring a multitarget approach, Aurinia aims to enhance the effectiveness of existing treatments, potentially leading to better preservation of kidney function and improved quality of life for patients. The study's outcomes could influence future treatment guidelines and offer new hope for those affected by this challenging condition.
What's Next?
The study will proceed with patient enrollment and data collection over the coming months. If successful, the results could lead to new combination therapies being recommended for lupus nephritis, potentially altering current treatment protocols. Stakeholders, including healthcare providers and patients, will be closely monitoring the study's progress and outcomes. Regulatory bodies may also consider the findings for future approvals and recommendations.
